Phase I, Single-center, Open Label, Fixed-sequence Cross-over Study to Evaluate the Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2018
At a glance
- Drugs Cabotegravir (Primary) ; Rifabutin
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 31 Aug 2018 Biomarkers information updated
- 17 Jan 2018 Status changed from recruiting to completed.
- 05 Sep 2017 Planned End Date changed from 31 Aug 2017 to 15 Sep 2017.